Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.

Perl AE, Kasner MT, Shank D, Luger SM, Carroll M.

Clin Cancer Res. 2012 Mar 15;18(6):1716-25. doi: 10.1158/1078-0432.CCR-11-2346. Epub 2011 Dec 13.

PMID:
22167413
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM.

Clin Cancer Res. 2009 Nov 1;15(21):6732-9. doi: 10.1158/1078-0432.CCR-09-0842. Epub 2009 Oct 20.

PMID:
19843663
[PubMed - indexed for MEDLINE]
Free Article
3.

Phospho-specific flow: fixating on the target.

Levis M.

Clin Cancer Res. 2012 Mar 15;18(6):1493-5. doi: 10.1158/1078-0432.CCR-11-3266. Epub 2012 Feb 2.

PMID:
22302900
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients.

Chow S, Minden MD, Hedley DW.

Exp Hematol. 2006 Sep;34(9):1183-91.

PMID:
16939811
[PubMed - indexed for MEDLINE]
5.

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.

Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey JA, Martelli AM.

Oncotarget. 2012 Dec;3(12):1615-28.

PMID:
23271044
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.

Meng H, Jin Y, Liu H, You L, Yang C, Yang X, Qian W.

J Hematol Oncol. 2013 Feb 18;6:18. doi: 10.1186/1756-8722-6-18.

PMID:
23415012
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy.

Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS.

Mod Pathol. 2008 Mar;21(3):231-7. Epub 2007 Dec 21.

PMID:
18157089
[PubMed - indexed for MEDLINE]
Free Article
8.

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL.

PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008.

PMID:
18215105
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR.

Cancer Res. 2005 Aug 15;65(16):7052-8.

PMID:
16103051
[PubMed - indexed for MEDLINE]
Free Article
10.

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.

Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M.

Blood. 2012 Sep 27;120(13):2679-89. Epub 2012 Jul 23.

PMID:
22826565
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Martelli AM, Evangelisti C, Chiarini F, McCubrey JA.

Oncotarget. 2010 Jun;1(2):89-103. Review.

PMID:
20671809
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.

Boehrer S, Galluzzi L, Lainey E, Bouteloup C, Tailler M, Harper F, Pierron G, Adès L, Thépot S, Sébert M, Gardin C, de Botton S, Fenaux P, Kroemer G.

Cell Cycle. 2011 Sep 15;10(18):3168-75. Epub 2011 Sep 15.

PMID:
21897118
[PubMed - indexed for MEDLINE]
Free Article
13.

Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.

Dieterlen MT, Bittner HB, Klein S, von Salisch S, Mittag A, Tárnok A, Dhein S, Mohr FW, Barten MJ.

Cytometry B Clin Cytom. 2012 May;82(3):151-7. doi: 10.1002/cyto.b.21005. Epub 2011 Dec 23.

PMID:
22213594
[PubMed - indexed for MEDLINE]
Free Article
14.

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.

Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L.

Curr Med Chem. 2007;14(19):2009-23. Review.

PMID:
17691943
[PubMed - indexed for MEDLINE]
15.

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT.

Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Review.

PMID:
22845486
[PubMed - indexed for MEDLINE]
16.

Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells.

Mise J, Dembitz V, Banfic H, Visnjic D.

Pathol Oncol Res. 2011 Sep;17(3):645-56. doi: 10.1007/s12253-011-9365-z. Epub 2011 Feb 19.

PMID:
21336564
[PubMed - indexed for MEDLINE]
17.

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ.

Cancer Res. 2006 Jul 1;66(13):6589-97.

PMID:
16818631
[PubMed - indexed for MEDLINE]
Free Article
18.

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.

Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, Staikou-Drakopoulou E, Patsouris E, Panayiotidis P, Medeiros LJ, Rassidakis GZ.

Mol Cancer. 2010 Nov 10;9:292. doi: 10.1186/1476-4598-9-292.

PMID:
21067588
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.

Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ.

Clin Cancer Res. 2006 Sep 1;12(17):5165-73.

PMID:
16951235
[PubMed - indexed for MEDLINE]
Free Article
20.

Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.

Berk L, Mita MM, Kreisberg J, Bedrosian CL, Tolcher AW, Clackson T, Rivera VM.

Cancer Chemother Pharmacol. 2012 May;69(5):1369-77. doi: 10.1007/s00280-011-1813-7. Epub 2012 Jan 10.

PMID:
22231376
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk